8-OH-PBZI

8-OH-PBZI

Clinical data
ATC code	none
Identifiers
IUPAC name (3aS,9bR)-3-propyl-1,2,3a,4,5,9b-hexahydrobenzo[e]indol-8-ol
CAS Number	251327-33-0^Y
PubChem CID	10353845
ChemSpider	8529297^Y
UNII	B8GYQ9JV5F
CompTox Dashboard (EPA)	DTXSID501028808
Chemical and physical data
Formula	C15H21NO
Molar mass	231.339 g·mol^−1
3D model (JSmol)	Interactive image
SMILES CCCN1CC[C@H]2[C@@H]1CCC3=C2C=C(C=C3)O
InChI InChI=1S/C15H21NO/c1-2-8-16-9-7-13-14-10-12(17)5-3-11(14)4-6-15(13)16/h3,5,10,13,15,17H,2,4,6-9H2,1H3/t13-,15+/m1/s1^Y Key:LJDRQPOQHHOXHM-HIFRSBDPSA-N^Y
(verify)

8-OH-PBZI is a drug used in scientific research which acts as a potent and selective agonist for the dopamine D₃ receptor.[1][2][3]

References

1. Scheideler MA, Martin J, Hohlweg R, Rasmussen JS, Naerum L, Ludvigsen TS, et al. (November 1997). "The preferential dopamine D3 receptor agonist cis-8-OH-PBZI induces limbic Fos expression in rat brain". European Journal of Pharmacology. 339 (2–3): 261–70. doi:10.1016/S0014-2999(97)01372-1. PMID 9473144.
2. Fink-Jensen A, Nielsen EB, Hansen L, Scheideler MA (January 1998). "Behavioral and neurochemical effects of the preferential dopamine D3 receptor agonist cis-8-OH-PBZI". European Journal of Pharmacology. 342 (2–3): 153–61. doi:10.1016/S0014-2999(97)01494-5. PMID 9548380.
3. Malik P, Andersen MB, Peacock L (August 2004). "The effects of dopamine D3 agonists and antagonists in a nonhuman primate model of tardive dyskinesia". Pharmacology, Biochemistry, and Behavior. 78 (4): 805–10. doi:10.1016/j.pbb.2004.05.019. PMID 15301939. S2CID 19410897.